Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Aug;2(4):134-138.
doi: 10.4088/pcc.v02n0406.

Rivastigmine for Alzheimer's Disease: Improvement Versus Reduced Worsening

Murray Raskind  1 , Vinod Kumar, Lisa Malaty, John Messina, Richard Hartman, Ravi Anand
Affiliations

Rivastigmine for Alzheimer's Disease: Improvement Versus Reduced Worsening

Murray Raskind et al. Prim Care Companion J Clin Psychiatry. 2000 Aug.

Abstract

BACKGROUND: Alzheimer's disease (AD) is the most common cause of dementia in later life. It is manifested by gradual and progressive decline in cognitive function and ability to perform activities of daily living (ADL) and the development of behavioral disturbances. Progressive reduction in functional ability reduces independence and quality of life and adversely affects caregivers and society. Therefore, benefit from any AD therapy may be obtained not only from improved function but also from stabilization or reduced worsening of function. METHOD: This retrospective study of pooled data from 3 randomized, placebo-controlled trials (N = 2126) compared the incidence of different levels of worsening between 2 rivastigmine treatment groups and a placebo group at week 26 for cognition, using the Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog); global functioning, using the Clinicians' Interview-Based Impression of Change-Plus (CIBIC-Plus); and ADL, using the Progressive Deterioration Scale (PDS). Categories of worsening analyzed for each scale were as follows: ADAS-Cog: any decline, >/= 4-point decline, >/= 7-point decline; CIBIC-Plus: stabilized/worsened (rating = 4, 5, 6, or 7), any worsening (rating = 5, 6, or 7); PDS: any worsening, >/= 10% worsening. RESULTS: Patients treated with rivastigmine, 6-12 mg/day, showed significantly less decline in cognition, global functioning, and ADL for all categories of worsening examined compared with patients who received placebo. The reduction in decline compared with placebo was greater in the group receiving 6-12 mg/day of rivastigmine compared with the treatment group receiving 1-4 mg/day of rivastigmine. CONCLUSION: Rivastigmine reduces the amount of worsening observed in cognition, global functioning, and ADL in a 6-month trial period.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Hypothetical Data Showing Annual Deterioration of Cognition in Alzheimer's Disease Measured by the Cognitive Portion of the Alzheimer's Disease Assessment Scale (ADAS-Cog)a
See this image and copyright information in PMC

References

    1. Mayeux R, Sano M. Treatment of Alzheimer's disease. N Engl J Med. 1999;341:1670–1679. - PubMed
    1. Katzman R. Alzheimer's disease. N Engl J Med. 1986;314:937–964. - PubMed
    1. Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry. 1982;140:566–572. - PubMed
    1. Mega MS, Cummings JL, Fiorella T, et al. The spectrum of behavioral changes in Alzheimer's disease. Neurology. 1996;46:130–135. - PubMed
    1. Anthony-Bergstone CR, Zarit SH, Gatz M. Symptoms of psychological distress among caregivers of dementia patients. Psychol Aging. 1988;3:245–248. - PubMed